Pixium Vision announces its cash position as of March 31, 2022, providing up-to-date information on activity and financial visibility through the end of 2022.

Pixium Vision announces cash position at March 31, 2022 And evaluate that activity and that activity Financial visibility through the end of 2022

Paris, 19 19 April 2022 – 7:00 am CET- Pixium Vision SA (Euronext Growth Paris – FR0011950641) is a bioelectronics company that develops innovative bionic vision systems that enable visually impaired patients to live more independently. We are currently announcing a cash position of € 10.4 million. We will contact you on March 31, 2022 about its major developments.

In total, Pixium Vision’s cash as of March 31, 2022 was € 10.4 million, compared to € 14.5 million as of January 1, 2022. The end of 2022.

Pixium Vision continues to seek several ways of remorse to secure the cash needed to pursue its development. In particular, we are investigating several recent funding offers. Pixium Vision will inform the market of the main terms of the offer at the appropriate time and decide to retain and submit it for shareholder approval at the next General Assembly if the schedule for convening the meeting permits.

Main developmentpeIn the first quarter of 2022

Highlights for the first quarter of 2022 will include the publication of peer-reviewed clinical data. Nature Communications Also, FDA approval for extension of feasibility study of Prima * system in the United States at Stanford University.

Last January, Pixium Vision announced the release of peer-reviewed clinical data. Nature CommunicationsShows the clinical benefits of the Prima * system in patients with dry AMD. Key findings include the fact that Prima System * implants were well tolerated over a period of 18-24 months, demonstrating simultaneous perception of natural and prosthetic vision.

In addition, in March last year, Pixium Vision announced at Stanford University’s Ophthalmology that the FDA has approved an extension of the feasibility study of the Prima * system in the United States. This new research site has been added to the first two sites: the UPMC Eye Center in Pittsburgh and the Buscom Palmer Eye Institute in Miami.

About Pixium Vision

Pixium Vision Create a world of bionic vision so that people who have lost sight can restore vision and gain autonomy. Pixium Vision’s bionic vision system is associated with the duration of surgery and rehabilitation. The Prima * system’s wireless photoelectrogenic subretinal microimplant is in clinical trials in patients who initially lose vision due to retinal degeneration due to dry age-related macular degeneration (dry AMD). increase. Pixium Vision works closely with academic partners and the world’s most prestigious vision research institutes, including Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, and the Institute of Ocular Microsurgery (IMO) in Barcelona. I am. , Bonn University Hospital and UPMC in Pittsburgh (Pennsylvania, USA). We are ENISO 13485 certified and have been certified as an “Innovative Company” by Bpifrance.

Forward-Looking Statements This press release contains forward-looking statements. We believe our forecasts are based on reasonable assumptions, but these forward-looking statements carry a lot of risk and uncertainty and actual results may differ materially from those forecasts. there is. For more information on risks and uncertainties in which our actual performance, financial position, performance or performance may differ from those contained in our forward-looking statements, please see our FY2021 Risk Factors section. please refer to. Annual financial reports and other documents that we submit to AMF. It is available on the AMF website (www.amf-france.org) or on our website.

For more information: http://www.pixium-vision.com/en

follow me @PixiumVision; www.facebook.com/pixiumvision


contact address

Pixium Vision
Providing Nonhoff
[email protected]
+33 1 76 21 47 68
relationship busy
LifeSci Advisors
Sophie Baumont
[email protected]
+33 6 27 74 74 49
Public relations activities for investors
LifeSci Advisors
Guillaume van Rentelgem
[email protected]
+41 76 735 01 31

* Caution: Experimental equipment. US regulations limit it to experimental use.

Easy to print, PDF and email